PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the following three upcoming investor conferences in October:

  • Stifel 2020 Immunology and Inflammation Virtual Summit: “The Potential for Treg Modifying and CAR T Therapies in Immunology” panel on Thursday, October 1, 2020 at 3:00 p.m. ET.
  • Jefferies Virtual Cell Therapy Summit: Fireside chat on Monday, October 5, 2020 at 8:30 a.m. ET.
  • Chardan 4th Annual Genetic Medicines Conference: Fireside chat on Tuesday, October 6, 2020 at 11:30 a.m. ET.

A live webcast of these presentations will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentations, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com


logo.png

Source: Cabaletta Bio

The press releases contained in this section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Cabaletta disavows any obligation to update the information contained in such press releases after the date of their issuance.